SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing heightened volatility and intense community debate as investors react to the company's latest quarterly results and forward guidance, with discussions centering on its aggressive revenue growth targets for 2030 and its expanding role in AI-driven compute architectures. While bullish participants highlight the stock's long-term potential as a critical component in next-generation AI infrastructure, bears are aggressively questioning the company's valuation multiples and the sustainability of its rapid price appreciation.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is seeing high volatility and heavy trading volume as investors debate its upcoming earnings report, with bulls highlighting the company's massive revenue growth and expanding commercial backlog while bears focus on high cash burn and valuation concerns. The community is actively discussing whether the company's aggressive growth trajectory justifies its market cap or if the current price action is simply a pre-earnings speculative pump followed by an inevitable correction.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors react to a quarterly report that beat revenue and user growth expectations but faced downward pressure due to cautious revenue guidance and the termination of a partnership. The community is actively debating the effectiveness of leadership and the company's long-term potential as a cash-flow-positive player in the AR and AI space.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility and intense community debate as investors weigh stellar earnings and aggressive AI-driven ad revenue growth against broader software sector weakness and concerns over valuation. While bulls are encouraged by record-breaking margins and the potential for a massive breakout, others are focused on institutional profit-taking and fears of a long-term software overhang.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Semiconductor bears are facing extreme pressure as a relentless melt-up in chip stocks continues to ignore valuation concerns and geopolitical risks. Community sentiment is deeply divided, with many traders frustrated by consistent after-hours rallies and a persistent disconnect between sector earnings and price action, leaving some to debate capitulation while others hold out for an expected correction.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is trending as investors weigh significant revenue growth and a record backlog against concerns regarding ongoing equity distribution and capital structure. The community is actively debating whether the recent heavy institutional selling indicates a long-term fundamental shift or a temporary supply overhang that creates an entry opportunity ahead of future space sector momentum.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is experiencing significant volatility following a weak revenue report and the surprise withdrawal of long-term guidance, leading to intense community debate over whether the sell-off is an overreaction or a fundamental shift in the company's growth trajectory. While some investors are panic-selling due to concerns over competitive pressures and distributor inventory issues, others are doubling down, viewing the current price as a buying opportunity given the company's strong gross margins and established product growth.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant market volatility and intense community discussion following recent earnings and ongoing debates regarding Elevidys demand. Investors are actively contrasting the stock's discounted valuation against its commercialized gene therapy portfolio and pipeline potential, with many speculating on the impact of upcoming regulatory catalysts and potential buyout scenarios.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is seeing intense market activity following an earnings report that highlighted record-breaking backlog and massive revenue growth, fueling a tug-of-war between optimistic investors citing data center demand and bearish traders focused on margin pressures. The community is actively debating whether the stock is undergoing a long-term structural re-rating driven by AI-powered infrastructure needs or if recent volatility represents an earnings-driven trap for retail shareholders.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) is experiencing intense volatility as investors debate whether current valuations represent a sustainable AI-driven secular trend or a speculative bubble prone to a sharp mean reversion. Community sentiment is deeply polarized, with some traders actively loading up on inverse ETFs and put options in anticipation of a pullback, while others remain committed to buying every dip, citing continued infrastructure demand and strong earnings momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +13.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

Hims & Hers Health, Inc. (HIMS) closed at $26.37 in the latest trading session, marking a -3.79% move from the prior day.

Hims & Hers Expands DTC Platform to Broaden Access to Personal Care

HIMS broadens its DTC platform with GLP-1 access, a new Benefits hub and global expansion to broaden convenient, personalized care.

If You Invested $1000 In Hims & Hers Health Stock 5 Years Ago, You Would Have This Much Today

Top Healthcare Stocks Worth Watching - May 4th

UnitedHealth Group, Johnson & Johnson, Medtronic, Intuitive Surgical, Hims & Hers Health, GE HealthCare Technologies, and Cardinal Health are the seven Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly traded companies involved...

Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vanguard Group Inc. Buys 1,407,651 Shares of Hims & Hers Health, Inc. $HIMS

Vanguard Group Inc. raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 7.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,925,666 shares of the company's stock after purchasing an...

Hims & Hers Health (HIMS) Expected to Announce Earnings on Monday

Hims & Hers Health (NYSE:HIMS) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

<ul class="summary-bullets"><li>Hims is expanding beyond telehealth with a push into hormone care, while building out at-home testing and virtual care services.</li><li>Peptides is also seen as the next growth driver, with Bank of America Securities flagging upside from upcoming FDA reviews that could open new revenue streams.</li><li>Hims has recently moved towards branded drugs via Novo Nordisk and Eli Lilly partnerships.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) jumped more than 1% overnight heading into Monday after CEO Andrew Dudum expressed interest in a firm claiming 86% accuracy in predicting heart attacks, after an investor flagged the tech as having “unreal value.”<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> ended 1% higher on Friday, with a marginal after-hours gain.&nbsp;<h2 class="st-heading-2">CEO Hints At Interest in Heart Test Firm&nbsp;</h2>Dudum&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/AndrewDudum/status/2051086467116728452">responded</a> with a brief “Message me” to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/ConorNeu/status/2050936917001474375">post on X</a> by Conor Neu, chief investment officer at Pier Asset Management. Neu said that he was “personally invested in a company that can tell you whether you will have a heart attack in the next 12 months. With 86% certainty. From a blood test.”&nbsp;He added that it was “weak at scaling” and urged that “someone please buy this and take it to the masses.”The comments come as Hims continues broadening its scope beyond telehealth prescriptions into more integrated healthcare offerings. Hims has recently been building out its hormone health business as a key growth area. The company launched Testosterone Rx+ last week, a once-daily pill that naturally increases testosterone levels.&nbsp;It builds on treatments introduced in September 2025 that use the Enclomiphene drug, which helps the body naturally produce its own testosterone while maintaining fertility. The company also added combination options that include Tadalafil, a medication commonly used to treat erectile dysfunction, for men with low testosterone.Testosterone Rx+ brings these elements together in a single pill, combining Enclomiphene with zinc, vitamins B6 and B12, and L-arginine, an amino acid that supports blood flow. According to the company, 95% of users saw their testosterone levels increase, with 80% reaching healthy levels within about two months.The program includes symptom screening, at-home lab testing and virtual care, reflecting a broader push toward continuous, data-driven treatment. Hims has also expanded its women’s health offerings with estrogen patch treatments for menopause and perimenopause.<h2 class="st-heading-2">Peptides Upside Fuels HIMS Shares</h2>Investor focus has recently shifted toward peptides as a potential new revenue driver. Last month, Bank of America Securities (BofA) called&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-premarket-bofa-upside-fda-peptide-glp1/cZJvfUWRIDc">an upside</a> for HIMS shares from upcoming FDA discussions between July 23 and July 24 to review several peptide substances for possible inclusion on the 503A Bulks List, which determines which ingredients can be used for compounded medications.BofA said the move could open new revenue opportunities and allow Hims to repurpose existing GLP-1 infrastructure toward peptide therapies. The firm also raised its valuation multiple assumption to 25.5x from 21.5x, though it noted that the review is only an initial step and not a guarantee of approval.&nbsp;The review follows a 2023 decision to restrict nearly 20 peptide substances due to safety concerns, including potential risks related to cancer and organ damage.<h2 class="st-heading-2">HIMS Faces GLP-1 Pressure&nbsp;</h2>The telehealth firm’s expansion into newer categories comes as regulatory scrutiny intensifies in the weight-loss drug market. The U.S. Food and Drug Administration (FDA) recently proposed restricting compounding of key GLP-1 ingredients such as Semaglutide and Tirzepatide, limiting the availability of lower-cost alternatives.Hims has already started shifting towards branded therapies through partnerships with Novo Nordisk and Eli Lilly, offering treatments including Wegovy, Ozempic, Zepbound and Mounjaro. The company has also launched waitlists for some of these drugs and introduced tiered pricing through its platform.Dudum previously compared the approach to Netflix’s early days, saying the focus is on expanding choice rather than relying on a single therapy. He had also said that Hims has already begun shipping Novo Nordisk medicines and expects to exceed a run rate of 100,000 Wegovy prescriptions per month.<h2 class="st-heading-2">How Do Retail Traders Feel About HIMS?</h2>On Stocktwits, retail sentiment for HIMS slipped to ‘bearish’ from ‘bullish’ levels a week ago amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_9ed43585b9.webp" alt="hims ss.png" width="972" height="143"><figcaption>HIMS sentiment and message volume as of May 3 | Source: Stocktwits</figcaption></figure>HIMS has declined 24% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cvkd-stock-retail-sentiment-peaks-fda-phase-3-blood-clot-drug/cZQMBE6Re7h">CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug&nbsp;</a>

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Jumps Overnight: CEO Eyes Heart Attack Prediction Firm With ‘Unreal’ Value

CEO Andrew Dudum replied “Message me” to an investor post calling the tech of a heart test firm of having “unreal value” and urging a buyer.

Equity

<ul class="summary-bullets"><li>The company launched Testosterone Rx+, a once-daily pill designed to help the body naturally increase testosterone levels.</li><li>The rollout follows a recent FDA order supporting expanded testosterone therapy use for men with low libido from idiopathic hypogonadism.</li><li>The testosterone push comes as the FDA proposes restricting compounding of GLP-1 ingredients such as Semaglutide and Tirzepatide.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) snapped a three-day losing streak on Thursday after the telehealth firm expanded its testosterone-care offering, creating a new growth pillar as competition intensifies across the crowded GLP-1 weight-loss market.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> ended over 3% higher at $27.17 on Thursday, snapping three straight sessions of losses. Shares also logged their second consecutive month of gains, up 31% in April.&nbsp;<h2 class="st-heading-2">Hims Turns Up Its Testosterone Push</h2>The company on Thursday introduced Testosterone Rx+, a once-daily pill that naturally increases testosterone levels, as part of its broader push into men’s hormone therapies following a recent regulatory push supporting the use of testosterone therapy.Recently, the U.S. Food and Drug Administration (FDA) encouraged sponsors of approved testosterone replacement therapies to explore a potential new indication for treating low libido from idiopathic hypogonadism.Hims began building its testosterone platform in September 2025, allowing providers to prescribe Enclomiphene-based treatments that help the body produce more of its own testosterone, while preserving fertility. The company also introduced combination therapy with Tadalafil, a medication used to treat erectile dysfunction, for men with low testosterone.&nbsp;Testosterone Rx+ builds on the same approach by combining Enclomiphene with zinc, vitamins B6 and B12, and L-arginine, an amino acid for better blood flow, in a single pill. According to company data, 95% of customers saw increases in testosterone levels, with 80% reaching optimal levels within 60 days.The program also includes symptom-screening tools, at-home lab testing kits, and virtual care through the platform.<h2 class="st-heading-2">GLP-1 Crackdown Lifts Testosterone Bet</h2>The testosterone expansion comes as regulators tighten oversight around compounded obesity medicines that have previously benefited telehealth firms.The FDA recently proposed excluding key GLP-1 ingredients, such as Semaglutide and Tirzepatide, from its 503B bulk list, which determines when outsourcing facilities can compound medicines from raw ingredients. The proposal could limit the large-scale availability of compounded versions and increase reliance on branded therapies, underscoring the importance of additional revenue engines, such as testosterone care, within Hims’ portfolio.Earlier this year, Novo Nordisk filed a patent infringement lawsuit related to compounded semaglutide offerings before reaching an agreement with Hims to provide access to FDA-approved versions of Wegovy and Ozempic through the platform.<h2 class="st-heading-2">GLP-1 Rivals Crowd The Field</h2>Competition across the weight-loss treatment ecosystem continues to intensify as Novo Nordisk and Eli Lilly scale blockbuster GLP-1 therapies, while large tech players such as Amazon also enter the weight-loss space.&nbsp;Firms such as Structure Therapeutics are advancing an oral GLP-1 candidate that showed more than 16% weight loss in mid-stage trials, while Altimmune is progressing its Pemvidutide program toward Phase 3 development after aligning trial plans with the FDA.Meanwhile, upcoming FDA reviews of peptide substances for possible inclusion on the federal 503A bulks list could create another lifeline for Hims to expand peptide-based treatment offerings on its platform.<h2 class="st-heading-2">How Do Retail Traders Feel About HIMS?</h2>On Stocktwits, retail sentiment was ‘bearish’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_58e90e4540.webp" alt="hims ss.png" width="976" height="140"><figcaption>HIMS sentiment and message volume as of May 1 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Cole_DeFranco/message/651971960">said</a>, “Peptides are coming in July. See you at $70 in September!”<stembedurl>https://stocktwits.com/Cole_DeFranco/message/651971960</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/wwmeinc/message/651934177">said</a>, Good to see the FDA helping the cause by making drug development a business that should be protected.”<stembedurl>https://stocktwits.com/wwmeinc/message/651934177</stembedurl>HIMS stock has declined 18% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-retail-no-vote-20m-share-plan-before-aml-results/cZQNDC3ReIp">SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results&nbsp;</a>

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded 

Hims & Hers Health Inc - According to company data, 95% of users saw testosterone increases, with 80% reaching optimal levels within 60 days.

According to company data, 95% of users saw testosterone increases, with 80% reaching optimal levels within 60 days.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest HIMS News

HIMSHims & Hers Health Inc